Infectious disease
On the other hand, when dealing with a novel coronavirus, a certain amount of speed and urgency is necessary. Professor Chris Molloy, Chief Executive Officer of the U.K,’s Medicines Discovery Catapult, told BioSpace that real-time data should be considered, with a different lens applied.
The University of Oxford in the U.K., with the National Immunisation Schedule Evaluation Consortium, is planning a trial to evaluate the use of first and second doses of different COVID-19 vaccines.
A few companies shared some big Phase III results this week. Here’s a look.
The vast majority of COVID-19 vaccines on the market or in development are administered through an injection, but Vaxart is attempting to develop an oral vaccine.
The collaboration is valued at €150 million (approximately $180 million). The two companies already have a history of working together.
Although designed for two doses, primary analysis of AstraZeneca and the University of Oxford’s Phase III data for its COVID-19 vaccine found it to have 76% efficacy after the first dose.
Although Gamestop dominated the financial news this week, surging more than 1,600% in January, Novavax actually saw greater growth in 2020, with year-to-year gains of 2,731% that exceeded those of all the coronavirus stocks.
Medical community struggles over how to help patients with long-lasting, serious side effects even after “recovering” from COVID-19 infection.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for February 2, 2021.
After months of touting its efficacy to the western world, the efficacy of Russia’s Sputnik V vaccine has been validated in a peer-reviewed study published in The Lancet.
PRESS RELEASES